# US 2008/0188438 A1 · Fra-1 expression in brain cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188438 A1
- Document ID: US20080188438A1
- Status: Published application
- Kind: A1
- Application number: 12/062,423
- Filed: 2008-04-03
- Published: 2008-08-07
- Earliest claimed: 2001-02-12
- Assignees: The Penn State Research Foundation
- Inventors: Waldemar Debinski; Denise M. Gibo
- Web page: https://patentgrep.com/patent/US20080188438A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/82: Translation products from oncogenes
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Fra-1 serves as a target for diagnosing and treating glioblastoma multiforme and related brain cancers. Cancer in a brain tissue sample is detected by analyzing expression of Fra-1 in the sample. Brain cancer is treated by modulating Fra-1 gene expression in cells of the cancer, and by inhibiting angiogenesis associated with the cancer by interfering with Fra-1 binding to a VEGF-D promoter.

## Claims

### Claim 1

A composition for treating cancer comprising an oligonucleotide molecule as identified by SEQ ID No.: 5.

### Claim 2 (depends on 1)

The composition of claim 1, wherein SEQ ID No.: 5 binds to fra-1 and inhibits Fra-1 expression.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition further comprises a cellular permabilization domain.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises a nucleic acid sequence that is 50% homologous to SEQ ID No.: 5.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition comprises a nucleic acid sequence that is 75% homologous to SEQ ID No.: 5.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition comprises a nucleic acid sequence that is 90% homologous to SEQ ID No.: 5.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition comprises a nucleic acid sequence that is 99.9% homologous to SEQ ID No.: 5.
